What is ADARx?
Established in 2019, ADARx Pharmaceuticals operates at the intersection of advanced molecular biology and clinical pharmacology. The company is currently developing a robust pipeline of RNA-targeting therapeutics, utilizing a proprietary platform that encompasses oligonucleotide inhibition, degradation, and editing. By integrating novel delivery technologies, ADARx aims to address unmet medical needs across diverse therapeutic areas. The firm's market position is defined by its commitment to precision medicine, leveraging cutting-edge science to create scalable solutions for genetic and chronic diseases, effectively positioning itself as a key player in the next generation of biotech innovation.
How much funding has ADARx raised?
ADARx has raised a total of $286M across 4 funding rounds:
Unspecified
$5M
Unspecified
$6M
Series B
$75M
Series C
$200M
Unspecified (2020): $5M, investors not publicly disclosed
Unspecified (2020): $6M, investors not publicly disclosed
Series B (2023): $75M supported by OrbiMed, SR One, Sirona Capital, and Lilly Asia Ventures
Series C (2023): $200M featuring TCG Crossover, T. Rowe Price, Bain Capital, and BlackRock
Key Investors in ADARx
TCG Crossover
TCG Crossover is a science-driven investment firm focused on advancing disruptive medicines and breakthrough therapies that have the potential to transform the healthcare sector.
T. Rowe Price
T. Rowe Price is a global asset management organization providing investment solutions through active management, independent research, and long-term fundamental analysis.
Bain Capital
Bain Capital is a leading private investment firm that applies deep sector expertise and flexible capital solutions to drive innovation and growth across its portfolio companies.
What's next for ADARx?
Following the recent capital infusion, ADARx Pharmaceuticals is well-positioned to transition from its current development phase into more advanced clinical trials. The strategic deployment of these funds will likely focus on expanding the company's internal pipeline and optimizing its proprietary delivery mechanisms. As the firm scales, the focus will shift toward regulatory milestones and potential commercialization partnerships. By maintaining a rigorous research-driven approach, ADARx is poised to solidify its influence in the RNA therapeutics landscape, potentially setting new standards for efficacy and patient outcomes in the treatment of complex, high-burden diseases.
See full ADARx company page
